Patents Represented by Attorney, Agent or Law Firm Tina M. Tucker
  • P70 S6 kinase inhibitor and EGFR inhibitor combination therapy
    Patent number: 8334293
    Abstract: The present invention provides a combination therapy comprising the compound 4-[4-[4-(4-fluoro-3-trifluoromethyl-phenyl)-1-methyl-1H-imidazol-2-yl]-piperidin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine, or a pharmaceutically acceptable salt thereof, and an EGFR inhibitor for use in the treatment of glioblastoma multiforme, adenocarcinomas of the colon, non-small-cell lung cancer, small-cell lung cancer, cisplatin-resistant small-cell lung cancer, ovarian cancer, leukemia, pancreatic cancer, prostate cancer, mammary carcinoma, renal cell carcimoma, multiple myeloma, Kaposis Sarcoma, Hodgkins lymphoma, lymphangioleiomyomatosis, Non-Hodgkins lymphoma or sarcoma.
    Type: Grant
    Filed: November 4, 2009
    Date of Patent: December 18, 2012
    Assignee: Eli Lilly and Company
    Inventor: Sandaruwan Geeganage
  • Oxazolo[5-4-b]pyridin-5-yl compounds
    Patent number: 8288548
    Abstract: The present invention provides oxazolo[5,4-b]pyridin-5-yl compounds useful in the treatment of cancer.
    Type: Grant
    Filed: November 17, 2011
    Date of Patent: October 16, 2012
    Assignee: Eli Lilly and Company
    Inventors: David Andrew Coates, Raymond Gilmour, Jose Alfredo Martin, Eva Maria Martin de la Nava
  • Compound useful as a c-Met inhibitor
    Patent number: 8268836
    Abstract: The present invention relates to a c-Met inhibitor or a pharmaceutically acceptable salt thereof useful in treating cancer mediated by activity of c-Met receptors.
    Type: Grant
    Filed: July 22, 2011
    Date of Patent: September 18, 2012
    Assignee: Eli Lilly and Company
    Inventor: Zhipei Wu
  • Vinyl indazolyl compounds
    Patent number: 8268869
    Abstract: The present invention provides vinyl indazolyl compounds useful in the treatment of cancer.
    Type: Grant
    Filed: May 4, 2010
    Date of Patent: September 18, 2012
    Assignee: Eli Lilly and Company
    Inventors: Daohong Chen, Hong-Yu Li, Genshi Zhao
  • AKT and P70 S6 kinase inhibitors
    Patent number: 8148387
    Abstract: The present invention provides AKT and p70 S6 kinase inhibitors of the formula: The present invention also provides pharmaceutical compositions comprising compounds of Formula I, uses of compounds of Formula I and methods of using compounds of Formula I.
    Type: Grant
    Filed: November 3, 2009
    Date of Patent: April 3, 2012
    Assignee: Eli Lilly and Company
    Inventors: Timothy Alan Shepherd, Robert Dean Dally, Sajan Joseph
  • Triazolyl aminopyrimidine compounds
    Patent number: 8114872
    Abstract: The present invention provides triazolyl aminopyrimidine compounds useful in the treatment of cancer.
    Type: Grant
    Filed: May 7, 2008
    Date of Patent: February 14, 2012
    Assignee: Eli Lilly and Company
    Inventors: Joyce Z. Crich, Delu Jiang, Hong-Yu Li, William Thomas McMillen, Jason Scott Sawyer, Melissa Kate Slater, Yan Wang, James Robert Henry, Hong Hu, Sachin Govindlal Maniar
  • Crystalline 2,5-dione-3-(1-methyl-1H-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1H-indol-3-yl]-1H-pyrrole mono-hydrochloride
    Patent number: 8114901
    Abstract: The present invention relates to crystalline 2,5-dione-3-(1-methyl-1H-indol-3-yl)-4-[1-(pyridin-2-yl-methyl)piperidin-4-yl]-1H-indol-3-yl]-1H-pyrrole mono-hydrochloride salt, a pharmaceutical formulation containing said salt and to methods for treating cancer and for inhibiting tumor growth using said salt.
    Type: Grant
    Filed: July 8, 2003
    Date of Patent: February 14, 2012
    Assignee: Eli Lilly and Company
    Inventors: Julie Kay Bush, Margaret Mary Faul, Susan Marie Reutzel-Edens
  • Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer
    Patent number: 8101628
    Abstract: The present invention provides novel imidazolidinonyl aminopyrimidine compounds believed to have clinical use for treatment of cancer through inhibiting Plk1. wherein: R1 hydrogen, hydroxy, halo, methyl, C1-C2 alkoxy, amino, or methylamino; R2 is hydrogen, halo, or cyano; R3 is hydrogen or halo; R4 is hydrogen, halo, or methyl; provided that at least two of R1, R2, R3, and R4 are hydrogen; R5 is hydrogen, halo, or methyl; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 11, 2007
    Date of Patent: January 24, 2012
    Assignee: Eli Lilly and Company
    Inventors: Harold Burns Brooks, Joyce Z. Crich, James Robert Henry, Hong-Yu Li, Melissa Kate Slater, Yan Wang
  • P70 S6 kinase inhibitors
    Patent number: 8093383
    Abstract: The present invention provides p70 S6 kinase inhibitors of the formula: pharmaceutical formulations comprising them, and methods for their use.
    Type: Grant
    Filed: March 2, 2009
    Date of Patent: January 10, 2012
    Assignee: Eli Lilly and Company
    Inventor: Sajan Joseph
  • Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer
    Patent number: 8063212
    Abstract: The present invention provides novel imidazolidinonyl aminopyrimidine compounds believed to have clinical use for treatment of cancer through inhibiting Plk1. Formula I wherein: R1 is aminomethyl, (C1-C3 alkyl)aminomethyl, di(C1-C2 alkyl)aminomethyl, N-ethyl-N-methyl-aminomethyl, 1-aminoethyl, 1-((C1-C2 alkyl)amino)-ethyl, 3,3,3-trifluoro-propylaminomethyl, ethynyl, 2-hydroxy-ethoxy, 2-hydroxyethylaminomethyl, 2-cyanoethylaminomethyl, morpholin-4-ylmethyl, methoxymethoxymethyl, cyclopropyl, 1-azetidinylmethyl, 1-pyrrolidinylmethyl, or 1,3-dioxolan-2-yl; R2 is hydrogen or halo; R3 is hydrogen or halo; provided that at least one of R2 and R3 is hydrogen; R4 is hydrogen, methyl, or halo; and is a single bond that is either present or absent, or pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 11, 2007
    Date of Patent: November 22, 2011
    Assignee: Eli Lilly and Company
    Inventors: Harold Burns Brooks, Joyce Z. Crich, James Robert Henry, Hong-Yu Li, Jason Scott Sawyer, Yan Wang
  • Triazolyl aminopyrimidine compounds
    Patent number: 8063035
    Abstract: The present invention provides triazolyl aminopyrimidine compounds useful in the treatment of cancer.
    Type: Grant
    Filed: May 7, 2008
    Date of Patent: November 22, 2011
    Assignee: Eli Lilly and Company
    Inventors: Joyce Z. Crich, James Robert Henry, Hong Hu, Delu Jiang, Hong-Yu Li, William Thomas McMillen, Jason Scott Sawyer, Melissa Kate Slater, Yan Wang
  • Inhibitors of AKT (protein kinase B)
    Patent number: 7998977
    Abstract: 4-[5-(2-Amino-ethanesulfonyl)-isoquinolin-7-yl]-phenol or a pharmaceutically acceptable salt thereof or a hydrate of the compound or the salt thereof as Akt inhibitors that are antineoplastic and/or antiviral agents as well as compositions comprising these compounds and methods of using these compounds.
    Type: Grant
    Filed: June 12, 2007
    Date of Patent: August 16, 2011
    Assignee: Eli Lilly and Company
    Inventors: Sajan Joseph, Renhua Li, Michael Ray Myers, Aktham Aburub, Jenny Pingqi Dai, Christopher Randall Schmid
  • Kinase inhibitors
    Patent number: 7863310
    Abstract: The present invention provides kinase inhibitors of Formula I:
    Type: Grant
    Filed: January 21, 2005
    Date of Patent: January 4, 2011
    Assignee: Eli Lilly and Company
    Inventors: Rosanne Bonjouklian, Robert Dean Dally, Alfonso de Dios, Mirian Filadelfa del Prado Catalina, Carmen Dominguez-Fernandez, Carlos Jaramillo Aguado, Beatriz Lopez de Uralde-Garmendia, Timothy Alan Shepherd
  • Kinase inhibitors
    Patent number: 7767674
    Abstract: The present invention provides kinase inhibitors of Formula I:
    Type: Grant
    Filed: June 15, 2005
    Date of Patent: August 3, 2010
    Assignee: Eli Lilly and Company
    Inventors: Tiechao Li, Mark Andrew Pobanz, Chuan Shih, Yong Wang, Boyu Zhong, Jesus Andres Blas, Alfonso De Dios, Beatriz Lopez De Uralde-Garmendia, Luisa Maria Martin Cabrejas
  • Kinase inhibitors
    Patent number: 7652015
    Abstract: The present invention provides kinase inhibitors of Formula (I). Wherein R1, R2, X and Z are as described herein, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 25, 2006
    Date of Patent: January 26, 2010
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Jesus Andres Blas de Blas, Alfonso De Dios, Kevin John Hudziak, Tiechao Li, Beatriz López De Uralde-Garmendia, Mary Margaret Mader, Michael Ray Myers, Mark Andrew Pobanz, Chuan Shih, Boyu Zhong
  • Kinase inhibitors
    Patent number: 7582652
    Abstract: The present invention provides kinase inhibitors of Formula I.
    Type: Grant
    Filed: January 25, 2005
    Date of Patent: September 1, 2009
    Assignee: Eli Lilly and Company
    Inventors: Rosanne Bonjouklian, Chafiq Hamdouchi, Chuan Shih, Alfonso De Dios, Miriam Filadelfa del Prado, Carlos Jaramillo Aguado, Pramila Kotiyan, Mary Margaret Mader, Sheila Pleite Selgas, Concepcion Sanchez-Martinez
  • Pyrazole-isoquinoline urea derivatives as p38 kinase inhibitors
    Patent number: 7582638
    Abstract: The present invention provides kinase inhibitors of Formula (I) wherein R1, R2, and X are as described herein, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 23, 2006
    Date of Patent: September 1, 2009
    Assignee: Eli Lilly and Company
    Inventors: Alfonso De Dios, Cristina Garcia-Paredes, Beatriz López de Uralde Garmendia, Mary Margaret Mader, Mark Andrew Pobanz, Chuan Shih, Boyu Zhong
  • [4-(Benzo[B]thiophen-2-yl) Pyrimidin-2-yl]-amine derivatives as IKK-beta inhibitors for the treatment of cancer and inflammatory diseases
    Patent number: 7547691
    Abstract: The present invention provides compounds of Formula I: useful in the treatment of cancer and inflammatory diseases.
    Type: Grant
    Filed: November 15, 2006
    Date of Patent: June 16, 2009
    Assignee: Eli Lilly and Company
    Inventors: Karl Robert Dahnke, Ho-Shen Lin, Michael Enrico Richett, Chuan Shih, Q May Wang, Bo Zhang
  • Pyrazolopyridine derivatives as pharmaceutical agents
    Patent number: 7365066
    Abstract: Novel pyrazolopyridine derivative compounds are disclosed and their use as pharmaceutical agents, in particular their use as TGF-beta signal transduction inhibitors useful in the treatment of cancer and other disease states influenced by TGF beta.
    Type: Grant
    Filed: September 16, 2003
    Date of Patent: April 29, 2008
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, Rosanne Bonjouklian, Junkai Liao, William Thomas McMillen, Brandon Lee Parkhurst, Jason Scott Sawyer, Jonathan Michael Yingling, Jeremy Schulenburg York
  • Amidophenoxyindazoles useful as inhibitors of c-Met
    Patent number: RE43878
    Abstract: The present invention provides amidophenoxyindazole compounds useful in the treatment of cancer.
    Type: Grant
    Filed: December 8, 2011
    Date of Patent: December 25, 2012
    Assignee: Eli Lilly and Company
    Inventors: Tiechao Li, Mark Andrew Pobanz, Chuan Shih, Zhipei Wu, Wei Jennifer Yang, Boyu Zhong